INT153912

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.46
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 12
Disease Relevance 4.64
Pain Relevance 0.95

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Lpar1) plasma membrane (Lpar1) cytoplasm (Lpar1)
signal transducer activity (Lpar1)
Anatomy Link Frequency
CPA 1
Lpar1 (Mus musculus)
Pain Link Frequency Relevance Heat
agonist 135 98.30 Very High Very High Very High
Spinal cord 48 91.84 High High
antagonist 135 72.72 Quite High
Neuropathic pain 86 72.40 Quite High
Sciatic nerve 8 63.28 Quite High
dorsal root ganglion 37 58.24 Quite High
Inflammation 12 55.60 Quite High
c fibre 9 55.12 Quite High
alcohol 18 54.12 Quite High
Pain 43 52.32 Quite High
Disease Link Frequency Relevance Heat
Apoptosis 135 99.98 Very High Very High Very High
Reprotox - General 1 9 99.12 Very High Very High Very High
Injury 54 97.68 Very High Very High Very High
Targeted Disruption 139 94.48 High High
Neointima 45 92.40 High High
Male Infertility 18 92.28 High High
Cancer 219 86.88 High High
Neuroblastoma 9 86.32 High High
Aging 18 85.36 High High
Shock 9 81.84 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
LPA binds to selective cell surface receptors to promote cell growth, survival, motility and differentiation.
LPA Binding (binds) of
1) Confidence 0.46 Published 2008 Journal Curr Drug Targets Section Abstract Doc Link 18691016 Disease Relevance 0.32 Pain Relevance 0.07
A second important issue is the time-dependent increase in LPA levels caused by injections of LPA as well as LPC.
LPA Binding (injections) of
2) Confidence 0.32 Published 2009 Journal Mol Pain Section Body Doc Link PMC2780384 Disease Relevance 0.18 Pain Relevance 0.14
Lysophosphatidic acid (LPA) is a small, ubiquitous phospholipid that acts as an extracellular signaling molecule by binding to and activating at least five known G protein-coupled receptors (GPCRs): LPA(1)-LPA(5).
LPA Binding (binding) of
3) Confidence 0.29 Published 2010 Journal Annu. Rev. Pharmacol. Toxicol. Section Abstract Doc Link 20055701 Disease Relevance 0.06 Pain Relevance 0
The ligand preference of LPA4 is LPA 18:1 > 18:0 > 16:0 > 14:0 > 1-O-alkyl glycerophosphate >1-O-alkenyl glycerophosphate, and the Kd for LPA 18:1 binding to the human orthologue is 77 nM (Noguchi et al., 2003).
LPA Binding (binding) of
4) Confidence 0.27 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.22 Pain Relevance 0
There is a wealth of evidence that links LPA, LPA3 and LPA1 to the regulation of prostate cancer cells (Qi et al., 1998; Prenzel et al., 1999; Im et al., 2000; Daaka, 2002; Guo et al., 2006; Hwang et al., 2006).
LPA1 Binding (links) of associated with reprotox - general 1
5) Confidence 0.24 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.77 Pain Relevance 0.10
It is important to note that circulating LPA bound to carrier proteins such as albumin is unable to activate PPAR?
LPA Binding (bound) of
6) Confidence 0.23 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.92 Pain Relevance 0.03
Conversely, LPA binds to (Kd= 2.3 ┬ÁM) and activates the S1P1 receptor as a low-affinity agonist (Lee et al., 1998).
LPA Binding (binds) of associated with agonist
7) Confidence 0.21 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.09 Pain Relevance 0.11
There is a wealth of evidence that links LPA, LPA3 and LPA1 to the regulation of prostate cancer cells (Qi et al., 1998; Prenzel et al., 1999; Im et al., 2000; Daaka, 2002; Guo et al., 2006; Hwang et al., 2006).
LPA Binding (links) of associated with reprotox - general 1
8) Confidence 0.21 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.72 Pain Relevance 0.10
As for GPR87, also for P2Y10: additional studies will be needed to establish whether LPA is their most potent endogenous ligand.
LPA Binding (ligand) of
9) Confidence 0.21 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0 Pain Relevance 0
Furthermore, with the exception of LPA5, the alkyl analogues of LPA are less potent agonists of the remaining LPA GPCR; however, 1-O-alkyl glycerophosphate is considerably more potent than LPA at PPAR?
LPA Binding (potent) of associated with agonist
10) Confidence 0.21 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.42 Pain Relevance 0.14
LPA-induced molecular complex between LPA2 and Siva-1 plays a major role in the anti-apoptotic effect of LPA.
LPA Binding (effect) of associated with apoptosis
11) Confidence 0.21 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.63 Pain Relevance 0
1-O-alkyl glycerophosphate 18:0 > LPA 18:1 > LPA 20:4 = LPA 16:0 = LPA 18:3 > farnesyl monophosphate > farnesyl diphosphate > LPA 18:0 > LPA 20:4 > CPA 18:1 > CPA 16:0 > N-arachidonyl glycine (Williams et al., 2009), and the Kd for LPA 18:1 binding is 6.4 nM (Kotarsky et al., 2006).
LPA Binding (binding) of in CPA
12) Confidence 0.21 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.32 Pain Relevance 0.25

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox